| 1. |
Grading system enhances confidence in guidelines |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
A traditional herbal asthma remedy termed 'fish medicine' has been challenged in court |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
COPD news from the 100th International Conference of the American Thoracic Society |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 4-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
According to current guidelines, treatment and control rates of hypertension among elderly adults are suboptimal, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
CR oxybutynin cost effective for OAB in France, Austria and the UK |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
GPI 15715*is an effective and well tolerated sedative for patients undergoing elective colonoscopy, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
A female testosterone patch may be effective for treatment of hypoactive sexual desire disorder |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Early antihypertensive therapy is superior to delayed therapy in patients with isolated systolic hypertension, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Positive results for rituximab revealed at ASCO |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 11-12
C Innes,,
Preview
|
|
摘要:
Maintenance therapy with the anti-CD20 antibody rituximab [Rituxan] following an initial course of chemotherapy produces marked improvements in progression-free survival among patients with indolent non-Hodgkin's lymphoma (NHL), according to a study presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) [New Orleans, US; June 2004]. After 2 years, almost twice as many rituximab recipients were free of disease progression, compared with those who received no further therapy (73% vs 43%). Other data presented at the meeting show extremely positive survival benefits for younger patients with aggressive NHL, and may change the standard of care for this disease. In this study, patients who received rituximab in combination with chemotherapy had an overall survival rate of 95% at 2 years. In a third study, previously untreated patients with mantle cell lymphoma (MCL) had significantly higher remission rates and prolonged time to treatment failure when treated with first-line rituximab plus chemotherapy, compared with chemotherapy alone.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Intravenous immunoglobulin (IVIG) may be useful in treating recurrentClostridium difficilediarrhoea |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1443,
2004,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
